Floatz Rating
B62/100
Confidence
Indicative
Sponsor
Roswell Park Cancer Institute
Modality
Small molecule
Development Phase
Phase 3
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
56High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT01684397CT.gov Pazopanib Hydrochloride and Bevacizumab in Treating Patients With Previously Untreated Metastatic Kidney Cancer | — | Active Not Recruiting | — | — | — |
NCT01727089CT.gov Bevacizumab With or Without TRC105 in Treating Patients With Metastatic Kidney Cancer | — | Completed | — | — | — |
NCT01243359CT.gov Sunitinib Malate and Bevacizumab in Treating Patients With Kidney Cancer or Advanced Solid Malignancies | — | Completed | — | — | — |
NCT01198158CT.gov Everolimus With or Without Bevacizumab in Treating Patients With Advanced Kidney Cancer That Progressed After First-Line Therapy | — | Terminated | — | — | — |
NCT01582009CT.gov Panobinostat and Everolimus in Treating Patients With Metastatic or Unresectable Renal Cell Cancer That Does Not Respond to Treatment With Sunitinib Malate or Sorafenib Tosylate | — | Terminated | — | — | — |
NCT01038778CT.gov Entinostat in Combination With Aldesleukin in Treating Patients With Metastatic Kidney Cancer | — | Active Not Recruiting | — | — | — |
NCT00890747CT.gov Sunitinib Malate in Treating HIV-Positive Patients With Cancer Receiving Antiretroviral Therapy | — | Completed | — | — | — |
NCT00378703CT.gov Bevacizumab, Sorafenib Tosylate, and Temsirolimus in Treating Patients With Metastatic Kidney Cancer | — | Completed | — | — | — |
NCT00499135CT.gov Sunitinib Malate in Treating Patients With Unresectable or Metastatic Kidney Cancer or Other Advanced Solid Tumors | — | Completed | — | — | — |
NCT00303862CT.gov AZD2171 in Treating Patients With Refractory Metastatic Kidney Cancer | — | Terminated | — | — | — |
Show 2 more trialsShow fewer
NCT00126503CT.gov Sorafenib Tosylate and Bevacizumab in Treating Patients With Advanced Kidney Cancer | — | Completed | — | — | — |
NCT00005799CT.gov Fludarabine Phosphate, Low-Dose Total Body Irradiation, and Donor Stem Cell Transplant in Treating Patients With Hematologic Malignancies or Kidney Cancer | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
73High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Nonpapillary Renal Cell Carcinoma
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Cediranib (this asset) | Roswell Park Cancer Institute | P3 | B · 62 |
| Girentuximab | Massachusetts General Hospital | P3 | BB |
| Pazopanib | Academic and Community Cancer Research United | P4 | BB |
| Clostridium Butyricum Miyairi 588 | City of Hope Medical Center | P3 | BB |
| Immunoglobulin G4, Anti-(Human Programmed Cell Death Protein 1) (Human Monoclonal Regn2810 Heavy Chain), Disulfide With Human Monoclonal Regn2810 .Kappa.-Chain, Dimer | Regeneron Pharmaceuticals | P2 | BB |
| Nivolumab | Fred Hutchinson Cancer Center | P3 | BB |
| Cabozantinib | SWOG Cancer Research Network | P3 | BB |
| Irinotecan | M.D. Anderson Cancer Center | P3 | B |
| Cyclophosphamide | City of Hope Medical Center | P3 | B |
+42 more in the Nonpapillary Renal Cell Carcinoma cohort
Other indications for Cediranib
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Gliosarcoma | — | P2 | BBB · 76 |
| Metastatic Melanoma | — | P2 | BBB · 73 |
| Adult Glioblastoma | — | P2 | BBB · 73 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
- GirentuximabMassachusetts General HospitalBB
- PazopanibAcademic and Community Cancer Research UnitedBB
- Clostridium Butyricum Miyairi 588City of Hope Medical CenterBB
- Immunoglobulin G4, Anti-(Human Programmed Cell Death Protein 1) (Human Monoclonal Regn2810 Heavy Chain), Disulfide With Human Monoclonal Regn2810 .Kappa.-Chain, DimerRegeneron PharmaceuticalsBB
- NivolumabFred Hutchinson Cancer CenterBB
Citation
Floatz Terminal. Cediranib in Nonpapillary Renal Cell Carcinoma. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/cediranib-nonpapillary-renal-cell-carcinoma
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →